Holen Sie sich die Stockscreener-App
13.46
0.60%
0.08
Schlusskurs vom Vortag:
$13.38
Offen:
$13.46
24-Stunden-Volumen:
71,382
Relative Volume:
0.05
Marktkapitalisierung:
$418.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-49.81M
KGV:
-6.243
EPS:
-2.156
Netto-Cashflow:
$-42.93M
1W Leistung:
-2.82%
1M Leistung:
+19.22%
6M Leistung:
+465.55%
1J Leistung:
+245.13%
1-Tages-Spanne:
$12.95
$13.71
1-Wochen-Bereich:
$12.63
$13.73
52-Wochen-Spanne:
$1.60
$16.49
Alto Neuroscience Inc Stock (ANRO) Company Profile
Firmenname
Alto Neuroscience Inc
Sektor
Branche
Telefon
773-255-5012
Adresse
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Vergleichen Sie ANRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
13.46 | 415.67M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.07 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
728.72 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.44 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
904.20 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.07 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-17 | Eingeleitet | BTIG Research | Buy |
| 2025-09-29 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-23 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-09-03 | Eingeleitet | Wedbush | Outperform |
| 2024-02-27 | Eingeleitet | Jefferies | Buy |
| 2024-02-27 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-27 | Eingeleitet | Stifel | Buy |
| 2024-02-27 | Eingeleitet | TD Cowen | Outperform |
| 2024-02-27 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Alto Neuroscience Inc Aktie (ANRO) Neueste Nachrichten
Will Alto Neuroscience Inc. stock announce special dividendWeekly Trade Summary & Verified Momentum Watchlists - Newser
Aug Wrap: Is Alto Neuroscience Inc. stock supported by strong fundamentalsJuly 2025 News Drivers & Precise Swing Trade Alerts - BỘ NỘI VỤ
What insider purchases suggest about Alto Neuroscience Inc. stockQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - Newser
Can Alto Neuroscience Inc. stock maintain growth trajectoryJuly 2025 Action & Daily Growth Stock Investment Tips - Newser
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08December 3, 2025 - BioSpace
Is Alto Neuroscience Inc. stock undervalued after correctionTrade Volume Summary & Long-Term Growth Plans - Newser
Can Alto Neuroscience Inc. stock double in next 5 yearsMarket Activity Report & Safe Investment Capital Preservation Plans - Newser
What technical patterns form on Alto Neuroscience Inc. stock chartsPortfolio Performance Summary & Step-by-Step Swing Trade Plans - Newser
Is Alto Neuroscience Inc. stock safe for risk averse investorsQuarterly Profit Report & AI Driven Price Forecasts - Newser
What dividend safety rating applies to Alto Neuroscience Inc. stockJuly 2025 PreEarnings & Real-Time Buy Zone Alerts - Newser
What sentiment indicators say about Alto Neuroscience Inc. stock - Newser
Short Covering: Why Alto Neuroscience Inc. stock remains undervaluedJuly 2025 Action & Advanced Technical Signal Analysis - BỘ NỘI VỤ
Can Alto Neuroscience Inc. stock test all time highsLayoff News & Risk Controlled Stock Pick Alerts - Newser
Is Alto Neuroscience Inc. stock a buy during volatile markets2025 Key Lessons & Expert Approved Momentum Trade Ideas - Newser
How strong dollar benefits Alto Neuroscience Inc. stockJuly 2025 Review & Risk Controlled Stock Alerts - Newser
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Biotech Co.'s Q3/25 Progress on Lead Programs Steady - streetwisereports.com
Biotech Co. Advances Precision Psychiatry Breakthrough Pipeline While Analysts' Sentiment Remains Positive - streetwisereports.com
Lost Money on Alto Neuroscience, Inc. (ANRO)? Contact Levi & Kors - The National Law Review
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026 (NYSE:ANRO) - Seeking Alpha
Alto Neuroscience files to sell 8.45M shares of common stock for holders - TipRanks
Alto Neuroscience (NYSE: ANRO) files to register 8,454,514 resale shares from $50M private placement - Stock Titan
Alto Neuroscience’s ALTO-101 Study: A Potential Game-Changer for Schizophrenia Treatment? - MSN
Alto Neuroscience Inc. (ANRO) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Why Alto Neuroscience Inc. stock attracts wealthy investorsJuly 2025 Levels & Technical Entry and Exit Tips - newser.com
How Alto Neuroscience Inc. stock expands through international marketsWeekly Trade Recap & Consistent Income Trade Recommendations - newser.com
Will Alto Neuroscience Inc. stock benefit from commodity prices2025 Technical Overview & Fast Momentum Entry Tips - newser.com
ANRO Builds Momentum: Pipeline Readouts And Cash Strategy Put 2026 In Spotlight - RTTNews
Quantitative breakdown of Alto Neuroscience Inc. recent move2025 Trading Volume Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Key resistance and support levels for Alto Neuroscience Inc.2025 Winners & Losers & Risk Managed Investment Strategies - newser.com
Volume spikes in Alto Neuroscience Inc. stock – what they mean - newser.com
Is Alto Neuroscience Inc. stock vulnerable to regulatory risksOptions Play & Scalable Portfolio Growth Ideas - newser.com
Is Alto Neuroscience Inc. stock a top pick for value investorsSell Signal & Smart Allocation Stock Tips - newser.com
Finanzdaten der Alto Neuroscience Inc-Aktie (ANRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):